Lista de obras - Li-Chuan Chan - Dominio Público Uruguay

CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer

scientific article published on 08 November 2019

Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer

artículo científico publicado en 2014

Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer

artículo científico publicado en 2018

Deubiquitination and Stabilization of PD-L1 by CSN5.

artículo científico publicado en 2016

Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1.

artículo científico publicado en 2018

Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth

scientific article published on 29 June 2018

GSK3β inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers.

artículo científico publicado en 2016

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity.

artículo científico publicado en 2016

IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion

scientific article published on 15 July 2019

In vivo growth suppression of CT-26 mouse colorectal cancer cells by adenovirus-expressed small hairpin RNA specifically targeting thymosin beta-4 mRNA.

artículo científico publicado en 2014

Juxtacrine signaling inhibits antitumor immunity by upregulating PD-L1 expression.

artículo científico publicado en 2018

Mechanisms Controlling PD-L1 Expression in Cancer

scientific article published on 24 October 2019

Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer

artículo científico publicado en 2019

New Approaches on Cancer Immunotherapy

scientific article published on 15 October 2019

Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression

artículo científico publicado en 2019

Palmitoylation stabilizes PD-L1 to promote breast tumor growth

scientific article published on 04 December 2018

STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion.

artículo científico publicado en 2018

Selective expression of constitutively active pro-apoptotic protein BikDD gene in primary mammary tumors inhibits tumor growth and reduces tumor initiating cells

artículo científico publicado en 2015

Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells

artículo científico publicado en 2019

Thymosin beta 4 induces colon cancer cell migration and clinical metastasis via enhancing ILK/IQGAP1/Rac1 signal transduction pathway.

artículo científico publicado en 2011

Thymosin beta-4 knockdown in IEC-6 normal intestinal epithelial cells induces DNA re-replication via downregulating Emi1.

artículo científico publicado en 2014

Use of a recombinant protein containing major epitopes of hnRNP G to detect anti-hnRNP G antibodies in dogs with systemic lupus erythematosus.

artículo científico publicado en 2006

Lista de obras de Li-Chuan Chan

CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer

Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer

Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer

Deubiquitination and Stabilization of PD-L1 by CSN5.

Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1.

Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth

GSK3β inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers.

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity.

IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion

In vivo growth suppression of CT-26 mouse colorectal cancer cells by adenovirus-expressed small hairpin RNA specifically targeting thymosin beta-4 mRNA.

Juxtacrine signaling inhibits antitumor immunity by upregulating PD-L1 expression.

Mechanisms Controlling PD-L1 Expression in Cancer

Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer

New Approaches on Cancer Immunotherapy

Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression

Palmitoylation stabilizes PD-L1 to promote breast tumor growth

STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion.

Selective expression of constitutively active pro-apoptotic protein BikDD gene in primary mammary tumors inhibits tumor growth and reduces tumor initiating cells

Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells

Thymosin beta 4 induces colon cancer cell migration and clinical metastasis via enhancing ILK/IQGAP1/Rac1 signal transduction pathway.

Thymosin beta-4 knockdown in IEC-6 normal intestinal epithelial cells induces DNA re-replication via downregulating Emi1.

Use of a recombinant protein containing major epitopes of hnRNP G to detect anti-hnRNP G antibodies in dogs with systemic lupus erythematosus.